TARG Targanta Therapeutics Corp (MM)

Targanta Therapeutics Corporation (Nasdaq: TARG) today announced its planned participation in the following investor conferences in September 2008: BioCentury and Thomson Reuters Newsmakers in the Biotech Industry Conference on Thursday, September 4, 2008 at 3:00 p.m. ET at the Millennium Broadway Hotel & Conference Center in New York, NY. Thomas Weisel Partners Healthcare Conference on Friday, September 5, 2008 at 8:35 a.m. ET in the Stewart Room of the Four Seasons Hotel in Boston, MA. Mark Leuchtenberger, President and Chief Executive Officer of Targanta, will be presenting at both conferences. The presentations will be webcast live and will be available for replay for approximately 30 days following the presentations through the Investor Relations section of Targanta�s website at www.targanta.com/investors. About Targanta Therapeutics Targanta Therapeutics Corporation (Nasdaq: TARG) is a biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company�s pipeline includes an intravenous version of oritavancin, a semi-synthetic lipoglycopeptide antibiotic currently awaiting U.S. and EU regulatory approval, and, a program to develop an oral version of oritavancin for the treatment of Clostridium difficile. The Company has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Qu�bec, Canada. For more information on Targanta, visit www.targanta.com.